Hepatitis C virus encoded proteins: Targets for antiviral therapy

Drugs of the Future

Volumn 25, Issue 9, 2000, Pages 933-944

  Wang, Q M ^a   Du, M X ^a   Hockman, M A ^a   Johnson, R B ^a   Sun, X L ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ANTIVIRUS AGENT; ENZYME INHIBITOR; HELICASE; HETEROCYCLIC COMPOUND; LACTONE; OXOACID; PACLITAXEL; PHENANTHRENE DERIVATIVE; PIPERIDINE DERIVATIVE; QUINONE DERIVATIVE; RD 2 4039; RD 4 6205; RNA POLYMERASE; SCH 351633; SCH 68631; SERINE PROTEINASE INHIBITOR; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS ENZYME; VIRUS PROTEIN; VIRUS RNA;

ANTIVIRAL ACTIVITY; ENZYME INHIBITION; HEPATITIS C; NONHUMAN; REVIEW; VIRUS GENOME; VIRUS HEPATITIS; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0033748847     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.09.659135     Document Type: Review

References (141)

1. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
2. Hepatitis C virus infection is associated with development of hepatocellular carcinoma
3. Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus subgroups
4. Molecular evolution of hepatitis viruses
5. Variability of the hepatitis C virus genome
6. Virology of hepatitis C virus
7. The molecular virology of hepatitis C
8. In vivo analysis of the 3' untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone
9. A second hepatitis C virus-encoded proteinase
10. Mechanism of autoproteolysis at the NS2-NS3 junction of the hepatitis C virus polyprotein
11. Hepatitis C virus NS3/4A protease
12. Structure and function of hepatitis C virus NS3 helicase
13. Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing
14. Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation
15. The non-structural 5A protein of hepatitis C virus
16. Hepatitis C virus RNA-dependent RNA polymerase
17. Strategies and prospects for vaccination against the hepatitis C viruses
18. Hepatitis C treatment
19. Recent advances in prevention and treatment of hepatitis C virus infections
20. Broadspectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: A comparison with ribavirin and demonstration of antiviral additivity with alpha interferon
21. Molecular virology of hepatitis C virus
22. Targets for inhibition of hepatitis C virus replication
23. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus
24. In vitro study of the NS2-3 protease of hepatitis C virus
25. Inhibition of hepatitis C virus NS2/3 processing by NS4A peptides. Implications for control of viral processing
26. Molecular characterization of hepatitis C virus
27. Crystal structure of the hepatitis C virus protease domain complexed with a synthetic NS4A cofactor peptide
28. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site
29. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo
30. Hepatitis C virus: An overview of current approach and progress
31. Recent progress on NS3 protease as an HCV drug target
32. The NS3/4A proteinase of the hepatitis C virus: Unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy
33. Identification of the sequence on NS4A required for enhanced cleavage of the NS5A/5B site by hepatitis C virus NS3 protease
34. In vitro cleavage of hepatitis C virus polyprotein substrates by purified recombinant NS3 protease
35. Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus
36. In vitro activity of hepatitis C virus protease NS3 purified from recombinant Baculovirus-infected Sf9 cells
37. Activity of purified hepatitis C virus protease NS3 on peptide substrates
38. An uniquely purified HCV NS3 protease and NS4A(21-34) peptide form a highly active serine protease complex in peptide hydrolysis
39. Use of a fluorescence plate reader for measuring kinetic parameters with inner filter effect correction
40. A high throughput assay of the hepatitis C virus nonstructural protein 3 serine proteinase
41. A continuous spectrophotometric assay for the hepatitis C virus serine protease
42. Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines
43. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: A 2.2 Angstrom resolution structure in a hexagonal crystal form
44. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional proteasehelicase
45. Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two protease-inhibitor complexes
46. Solution structure of substrate-based ligands when bound to hepatitis C virus NS3 protease domain
47. Structure of Sch 68631: A new hepatitis C virus proteinase inhibitor from Streptomyces sp.
48. Hepatitis C virus protease inhibitors: Thiazolidine derivatives
49. Novel hepatitis C virus protease inhibitors: 2,4,6-Trihydroxy, 3-nitro-benzamide derivatives
50. Non-peptide inhibitors for HCV serine protease
51. Isolation and structure of Sch 351633: A novel hepatitis C virus (HCV) protease inhibitor from the fungus Penicillium griseofulvum
52. Peptide-based inhibitors of the hepatitis C virus serine protease
53. Product inhibition of the hepatitis C virus NS3 protease
54. Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease
55. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products
56. Alpha-ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 protease
57. The design and synthesis of potent inhibitors of hepatitis C virus NS3-4A proteinase
58. Synthesis of two novel cyclic diphenyl ether analogs of an inhibitor of HCV NS3 protease
59. Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires
60. Affinity selection of a camelized V(H) domain antibody inhibitor of hepatitis C virus NS3 protease
61. A loop-mimetic inhibitor of the HCV-NS3 protease derived from a minibody
62. Design of selective eglin inhibitors of HCV NS3 proteinase
63. Interscaffolding additivity. Association of P1 variants of eglin c and of turkey ovomucoid third domain with serine proteinases
64. Unwinding RNA in Saccharomyces cerevisiae: DEAD-box proteins and related families
65. Virus-encoded RNA helicases
66. Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes
67. The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3)
68. Detection of hepatitis C virus helicase activity using the scintillation proximity assay system
69. An ELISA for RNA helicase activity: Application as an assay of the NS3 helicase of hepatitis C virus
70. Crystal structure of RNA helicase from genotype 1b hepatitis C virus. A feasible mechanism of unwinding duplex RNA
71. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: The crystal structure provides insights into the mode of unwinding
72. Helicase, a target for novel inhibitors of hepatitis C virus
73. Crystallographic structure of the amino terminal domain of yeast initiation factor 4A, a representative DEAD-box RNA helicase
74. Crystal structure of the ATPase domain of translation initiation factor 4A from Saccharomyces cerevisiae, the prototype of the DEAD box protein family
75. Developments in hepatitis C during 1996-1997
76. Isolation of RNA aptamers specific to the NS3 protein of hepatitis C virus from a pool of completely random RNA
77. Biochemical properties of a minimal functional domain with ATP-binding activity of the NTPase/helicase of hepatitis C virus
78. ATP-binding domain of NTPase/helicase as a target for hepatitis C virus therapy
79. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins
80. A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro
81. The N-terminal region of hepatitis C virus nonstructural protein 3 (NS3) is essential for stable complex formation with NS4A
82. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus
83. Expression, identification and subcellular localization of the proteins encoded by the hepatitis C viral genome
84. Hyperphosphorylation of the hepatitis C virus NS5A protein requires an active NS3 protease, NS4A, NS4B, and NS5A encoded on the same polyprotein
85. Modulation of hepatitis C virus NS5A hyperphosphorylation by nonstructural proteins NS3, NS4A, and NS4B
86. Hepatitis C virus nonstructural protein NS4B transforms NIH3T3 cells in cooperation with the Ha-ras oncogene
87. Hepatitis C virus nonstructural region 5A protein is a potent transcriptional activator
88. Hepatitis C virus NS5A protein modulates transcription through a novel cellular transcription factor SRCAP
89. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: Molecular mechanisms of kinase regulation
90. Hepatitis C virus RNA polymerase and NS5A complex with a SNARE-like protein
91. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling
92. Screening methods to identify agents that selectively inhibit hepatitis C virus replication
93. Hepatitis C virus NS5B protein is a membrane-associated phosphoprotein with a predominantly perinuclear localization
94. RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region
95. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity
96. A recombinant hepatitis C virus RNA-dependent RNA polymerase capable of copying the full-length viral RNA
97. De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus
98. De novo RNA synthesis catalyzed by HCV RNA-dependent RNA polymerase
99. De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase
100. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus
101. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus
102. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site
103. Biochemical and kinetic analyses of NS5B RNA-dependent RNA polymerase of the hepatitis C virus
104. Expression of hepatitis C virus NS5B protein: Characterization of its RNA polymerase activity and RNA binding
105. Specificity and mechanism analysis of hepatitis C virus RNA-dependent RNA polymerase
106. Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli
107. Gliotoxin: Inhibitor of poliovirus RNA synthesis that blocks the viral RNA polymerase 3Dpol
108. Biochemical characterization of a hepatitis C virus RNA-dependent RNA polymerase mutant lacking the C-terminal hydrophobic sequence
109. Processing in the hepatitis C virus E2-NS2 region: Identification of p7 and two distinct E2-specific products with different C termini
110. Transcriptional repression of p53 promoter by hepatitis C virus core protein
111. Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-β receptor
112. The core protein of hepatitis C virus induces hepatocettular carcinoma in transgenic mice
113. Hepatitis C virus core protein interacts with heterogeneous nuclear ribonucleoprotein K
114. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis
115. Inhibition of tumor necrosis factor (TNF-α)-mediated apoptosis by hepatitis C virus core protein
116. Hepatitis C virus core protein binds to apolipoprotein All and its secretion is modulated by fibrates
117. Hepatitis C virus core protein binds to a DEAD box RNA hellicase
118. Hepatitis C virus core protein interacts with a human DEAD box protein DDX3
119. Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor α-mediated apoptosis via NF-κB activation
120. Hepatitis C virus core protein interacts with cellular putative RNA helicase
121. Hepatitis C virus core protein-induced loss of LZIP function correlates with cellular transformation
122. Hepatitis C virus core protein interacts with 14-3-3 protein and activates the kinase Raf-1
123. Interaction between hepatitis C virus core protein and E1 envelope protein
124. Interaction of hepatitis C virus core protein with viral sense RNA and suppression of its translation
125. Hepatitis C virus core protein: Possible roles in viral pathogenesis
126. Properties of the hepatitis C virus core protein: A structural protein that modulates cellular processes
127. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein
128. Binding of hepatitis C virus to CD81
129. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor CD81